Eylea

Treatment of neovascular (wet) age-related macular degeneration (AMD); macular edema (ME) secondary to central retinal vein occlusion (CRVO); macular edema secondary to branch retinal vein occlusion (BRVO); diabetic macular edema (DME); myopic choroidal neovascularization (myopic CNV).

Intravitreal inj Wet AMD 2 mg (equiv to 50 microL). Initiated w/ 1 inj/mth for 3 consecutive mth, followed by 1 inj every 2 mth. Treatment interval may be maintained at 2 mth or further extended using a treat-&-extend dosing regimen. ME secondary to CRVO 2 mg (equiv to 50 microL). After initial inj, treatment is given mthly (every 4 wk) until visual &/or anatomic outcomes are stable for ≥3 mthly inj, interval between 2 doses should not be shorter than 1 mth. Continue treatment & the interval may be extended based on visual & anatomic outcomes (treat & extend regimen). ME secondary to BRVO 2 mg (equiv to 50 microL). After initial inj, treatment is given mthly (every 4 wk) until visual &/or anatomic outcomes are stable for ≥3 mthly inj, interval between 2 doses should not be shorter than 1 mth. Continue treatment & the interval may be extended based on visual & anatomic outcomes (treat & extend regimen). DME 2 mg (equiv to 50 microL) mthly for the 1st 5 consecutive doses, followed by 1 inj every 2 mth. Based on visual &/or anatomic outcomes, treatment interval may be maintained at 2 mth or individualized such as w/ a treat-&-extend dosing regimen, where treatment intervals are usually increased by 2-wk increments. Myopic CNV 2 mg (equiv to 50 microL) as a single inj. Additional doses only if disease persists.

Hypersensitivity. Ocular or periocular infection. Active severe intraocular inflammation.

Endophthalmitis, increased IOP, patients w/ poorly controlled glaucoma. May affect ability to drive or operate machinery. Women of childbearing potential should use effective contraception during treatment & for at least 3 mth after the last intravitreal inj. Pregnancy & lactation.

Conjunctival hemorrhage, eye pain. Retinal pigment epithelium tear or detachment, cataract, cortical, nuclear or subcapsular cataract, corneal erosion or abrasion, increased IOP & lacrimation, blurred vision, vitreous floaters or detachment, corneal edema, inj site pain & hemorrhage, foreign body sensation in eyes, eyelid edema, punctate keratitis, conjunctival & ocular hyperemia.

Other Eye Preparations

S01LA05 - aflibercept ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.

Rx